VAXIMM is developing oral T-cell immunotherapies for cancer patients. Its technology is based on first-in-class oral T-cell activators, using modified attenuated bacteria carrying a eukaryotic expression plasmid, which enables the targeting of tumor-related antigens, including personalized neoantigens.

Location

Canton

Facts & figures

  • Type of organization
    Private company
  • Year of foundation
    2008
  • Number of employees in Switzerland
    1-9

Key business

Keep browsing

You may also be interested in